Emerald Bio
7869 NE Day Road West
Bainbridge Island
Washington
98110
United States
Tel: 888-780-8588
Fax: Fax n/a
Website: http://www.emeraldbiosystems.com/
Email: systemswebcontact@embios.com
21 articles about Emerald Bio
-
Emerald Bioscience Launches Rebrand Including Name Change to Skye Bioscience
1/19/2021
Skye Bioscience, Inc. (OTCQB: SKYE) (“SKYE” or the “Company”), a biopharmaceutical company focused on developing proprietary, synthetic cannabinoid-derived molecules to treat glaucoma and other diseases with significant unmet need, has changed its name from Emerald Bioscience, Inc. to Skye Bioscience, Inc.
-
Emerald Bioscience to Present at the KCSA Cannabis Investor Conference
1/5/2021
Emerald Bioscience, Inc. (OTCQB: EMBI) (“Emerald” or the “Company”), a biopharmaceutical company focused on developing differentiated, proprietary cannabinoid derived molecules to treat glaucoma and other diseases with significant unmet needs, announced today that Punit Dhillon, CEO, Emerald Bioscience will be presenting at the KCSA Cannabis Investor Conference on Thursday, January 7, 2021. Presentation details are as follows: Event: K
-
Emerald Bioscience Provides Corporate Update
9/30/2020
Renewed team and capital focused on advancing lead compound for glaucoma into human studies Ongoing development of lead compound, THCVHS, includes near-term preclinical assessments of neuroprotection and comparison with leading glaucoma treatments Preclinical studies of CBDVHS will examine its utility for ocular, neurological, pain and addiction disorders San Diego, Calif., Sept. 30, 2020 (GLOBE NEWSWIRE) -- Emerald Bioscience, Inc. (OTCQB: EMBI) (“Emerald” or the “Company”), a prec
-
Emerald Bioscience to Present at the H.C. Wainwright 22nd Annual Global Investment Conference
9/3/2020
Emerald Bioscience, Inc. (OTCQB: EMBI a preclinical-stage biopharmaceutical company focused on the development of proprietary first-in-class molecules with strong clinical and commercial differentiation, announced today that Punit Dhillon, CEO, Emerald Bioscience will present a corporate overview at the H.C. Wainwright 22nd Annual Global Investment Conference on Tuesday, September 15, 2020. Mr. Dhillon will also be available for virtual one-o
-
Emerald Bioscience Appoints Biotech Veteran Dr. Margaret Dalesandro to Board of DirectorsRenewed team and capital focused on advancing lead compound for glaucoma into clinical development
8/13/2020
Emerald Bioscience, Inc. (OTCQB: EMBI) (“Emerald” or the “Company”), a preclinical-stage biopharmaceutical company focused on the development of proprietary first-in-class molecules with strong clinical and commercial differentiation, today announced the appointment of Margaret R. Dalesandro, Ph.D., to the Company's Board of Directors. Dr. Dalesandro brings more than 25 years of drug development experience in pharmaceutical, biotechnology a
-
Emerald Bioscience Appoints Biotech Executive Punit Dhillon as CEO
8/10/2020
Emerald Bioscience, Inc. (OTCQB: EMBI) (“Emerald” or the “Company”), a preclinical-stage biopharmaceutical company focused on the development of proprietary first-in-class molecules with strong clinical and commercial differentiation, today announced that Punit Dhillon, Chairman of the Board, has been appointed Chief Executive Officer of the
-
Emerald Bioscience Announces Pricing of $7.0 Million Upsized Registered Offering
7/31/2020
Emerald Bioscience, Inc. (OTCQB: EMBI) (“Emerald”), a biopharmaceutical company focused on bioengineered cannabinoid-based therapeutics to address global medical indications, today announced that it has priced a registered offering of an aggregate of 116,666,668 units, each consisting of (i) one share of common stock (or common stock equivalent), and (ii) one warrant to purchase one share of common stock, at a purchase price of $0.06 per unit.
-
Emerald Bioscience Announces Presentation of Cannabidiol-Valine-Hemisuccinate Ocular Data at Virtual ARVO® Meeting
6/9/2020
Bio-engineered analog of CBD (CBDVHS) exhibited highly significant potency when compared to CBD in lowering biomarkers associated with inflammation and fibrosis in a validated human tissue model of ocular disease Contrary to historical studies of CBD, CBDVHS was not associated with an elevation in intraocular pressure Long Beach, Calif., June 09, 2020 (GLOBE NEWSWIRE) -- -- Emerald Bioscience, Inc. (OTCQB: EMBI), focused on the development of cannabinoid-based therapeutics to address g
-
Emerald Bioscience Announces Awarding of Patent for Cannabidiol-Valine-Hemisuccinate in JapanThird largest pharmaceutical market in the world adds to the global patent footprint of the proprietary analog of CBD
6/2/2020
Emerald Bioscience, Inc. (OTCQB: EMBI), focused on the development of cannabinoid-based therapeutics to address global medical indications, especially those of unmet medical need, today announced that the company’s proprietary analog of cannabidiol, cannabidiol-valine-hemisuccinate (CBDVHS) has been awarded a patent in Japan that covers composition of matter claims and multiple methods of use. This molecule, licensed from the University
-
Emerald Bioscience Joins Alliance for Biosecurity
4/8/2020
Emerald Bioscience, Inc. today announced that the company has accepted an invitation to join the Alliance for Biosecurity. The Alliance, based in Washington, DC, is
-
Emerald Bio Announces New Partnership To Study Therapeutic Targets In Space
1/8/2014
-
Emerald Bio and SSGCID Solve More Than 620 Protein Structures From Infectious Disease Organisms
9/30/2013
-
Emerald Bio Makes Imagination the Only Limit to Protein Purification
4/3/2013
-
Emerald Bio and Nanoracks Test Space's Microgravity as a New Lab for Drug Discovery
3/13/2013
-
Emerald Bio to Highlight Strategies for Accelerating Drug Discovery and Reducing Risk at Biophysical Society's Annual Meeting
1/31/2013
-
Emerald Bio Showcases Improvements in Protein Purification Efficiency and Effectiveness at PEP TALK 2013
1/22/2013
-
BioBlocks, Inc. and Emerald Bio Align to Speed and Streamline Discovery of Small-Molecule Drugs
1/8/2013
-
Emerald Bio, the Science and Technology Facilities Council (STFC) and the University of Oxford Announce a Partnership for PiMS Commercial Software
11/27/2012
-
Emerald Bio and SomaLogic, Inc. Scientists Publish First Crystal Structure of Somamer Bound to Its Protein Target
11/13/2012
-
Emerald Bio Announces Unprecedented Multi-Target 3D Structural Biology Success
6/13/2012